Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report) was the target of a large drop in short interest in the month of July. As of July 15th, there was short interest totaling 200 shares, a drop of 97.2% from the June 30th total of 7,045 shares. Based on an average trading volume of 3,664 shares, the short-interest ratio is presently 0.1 days.
Clinuvel Pharmaceuticals Stock Performance
OTCMKTS:CLVLY opened at $7.35 on Friday. The firm’s fifty day simple moving average is $6.96 and its 200 day simple moving average is $7.22. Clinuvel Pharmaceuticals has a twelve month low of $5.98 and a twelve month high of $9.00.
About Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.
The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.
Featured Stories
- Five stocks we like better than Clinuvel Pharmaceuticals
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
